A 2024 RCT found semaglutide reduced hipbonedensityby 2.6% and lumbar spine by 2.1% in one year. Here is what the evidence says about protecting yourbonesandmuscle onGLP-1therapy.
GLP-1sare linked to a higher risk for osteoporosis, gout, and osteomalacia in people with type 2 diabetes and obesity, new research suggests, though an additional study also points to better ...

Such details provide a deeper understanding and appreciation for Bone Density Loss And Glp-1 Imbalance On Keto.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as Ozempic (semaglutide) and Wegovy (semaglutide), are widely used for treating type 2 diabetes and weightloss. Recent studies highlight potential risks tobonemineraldensity(BMD) and fracture risk, particularly in specific patient populations. Incorporating a regular exercise routine can help mitigate potentialbonelossfromGLP...

Aims Glucagon-like peptide-1 receptor agonist (GLP-1RA) may promoteboneformation, but conversely, they could also weakenbonesdue to the reduction in mechanical load associated with weightloss. ...

Two randomized control clinical trials reported conflicting effects onbonemineral content (BMC) andbonemineraldensity(BMD): one trial demonstrated preservation of BMC withGLP-1use, while the other found no significant difference in BMC or BMD between treatment and control groups.
DoGLP-1scauseboneloss? According to Dr Rajan, a drop inbonemineraldensitycan occur with weightlossonGLP-1medications - but he stresses that this isn't unique to these drugs.
As a result, when choosing a diabetes treatment, whether the drug affectsbonedensityshould be taken into account. The goal of this study was to determine how switching from dipeptidyl peptidase-4 inhibitors (DPP-4i) to glucagon-like peptide-1 receptor agonists (GLP-1RA) influencedbonemineraldensity(BMD) in diabetic patients.